John Overdeck’s Inhibrx, Inc. Common Stock INBX Stock Holding History

John Overdeck’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-78,400	Closed	-$2.74M	–	3470
2024 Q1	$2.74M	Buy	78,400 +70,500	+892%	+$2.57M	0.01%	1278
2023 Q4	$300K	Sell	7,900 -199,770	-96%	-$4.28M	﹤0.01%	2697
2023 Q3	$3.81M	Sell	207,670 -52,750	-20%	-$1.1M	0.01%	1038
2023 Q2	$6.76M	Sell	260,420 -75,383	-22%	-$1.76M	0.02%	809
2023 Q1	$6.34M	Buy	335,803 +89,802	+37%	+$2.09M	0.02%	797
2022 Q4	$6.06M	Buy	246,001 +82,512	+50%	+$2.43M	0.02%	772
2022 Q3	$2.94M	Buy	163,489 +39,264	+32%	+$708K	0.01%	979
2022 Q2	$1.41M	Buy	124,225 +66,452	+115%	+$978K	﹤0.01%	1379
2022 Q1	$1.29M	Buy	+57,773	New	+$1.47M	﹤0.01%	1576
2021 Q2	–	Sell	-17,688	Closed	-$355K	–	4835
2021 Q1	$355K	Buy	+17,688	New	+$516K	﹤0.01%	3208

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

John Overdeck's INBX Position: Q2 2024 in Review

John Overdeck sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 78,400 shares — an estimated $2.74M sold.

John Overdeck first reported a position in INBX in Q1 2021 and held it in 10 quarters. The position peaked at $6.76M in Q2 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

John Overdeck reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
John Overdeck sold 78,400 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $2.74M.
John Overdeck first reported a position in Inhibrx, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
John Overdeck's Inhibrx, Inc. Common Stock position peaked at $6.76M in Q2 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.